Earnings History Data for Mesoblast Limited (MESO) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Mesoblast Limited

Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
27-02-2023	AH		MESO	Mesoblast Limited	487.00	-0.17	-0.15	0.00		3.32	0.12 (3.75%)	3.30	0.10 (3.12%)	2.14 - 4.94	77,260	100,000	693

22-11-2022	PM		MESO	Mesoblast Limited	455.21	-0.12	-0.09	-0.17	Mesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82M [11/23/2022 2:11 AM]	3.35	0.10 (3.08%)	3.41	0.16 (4.92%)	2.14 - 6.92	82,156	80,000	1,500
Mesoblast GAAP EPS of -$0.0243 beats by $0.14, revenue of $1.5M misses by $1.82M [11/23/2022 2:11 AM] Mesoblast Financial Results and Corporate Update Webcast [Nov-21-22 06:00AM] Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 [Nov-22-22 06:01PM] Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) [Nov-22-22 06:32PM] Mesoblast Lead Product Shows Durable Long-Term Survival At Four Years In Kids With Graft Versus Host Disease [Nov-23-22 09:38AM]
30-08-2022	PM		MESO	Mesoblast Limited	437.11	-0.17	-0.08	-0.17	Mesoblast GAAP EPS of -$0.14, revenue of $10.21M [8/31/2022 5:16 AM]	3.00	0.27 (9.89%)	2.89	0.16 (5.86%)	2.14 - 7.28	75,242	50,000	2,452
Mesoblast GAAP EPS of -$0.14, revenue of $10.21M [8/31/2022 5:16 AM] Mesoblast Corporate Update and Financial Results Webcast [Aug-29-22 08:14PM] Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022 [Aug-30-22 07:05PM]
23-11-2021	AH	After the close (Nov 23)	MESO	Mesoblast Limited	810.00	-0.17	-0.15	0.00	Mesoblast EPS beats by $0.10, beats on revenue [11/23/2021 11:00 PM]	6.36	-0.11 (-1.70%)	6.23	-0.24 (-3.67%)	5.52 - 17.41	92,010	190,000	673
Mesoblast EPS beats by $0.10, beats on revenue [11/23/2021 11:00 PM] Operational Highlights and Financial Results for the Period Ended September 30, 2021 [Nov-23-21 06:09PM] Mesoblast Corporate Update and Financial Results Webcast [Nov-23-21 07:18AM] Mesoblast Announces Debt Refinancing And Expansion With Oaktree Capital [Nov-22-21 06:51AM]
02-06-2021	PM	After the close (Jun 2)	MESO	Mesoblast Limited	999.39	-0.22	-0.10	-0.14	Mesoblast reports FQ3 results [6/3/2021 1:34 AM]	7.09	-0.45 (-5.97%)	7.32	-0.22 (-2.92%)	6.67 - 21.28	205,854	130,000	1,998
Mesoblast reports FQ3 results [6/3/2021 1:34 AM] Mesoblast Corporate Update and Financial Results Webcast [Jun-02-21 06:01PM] Operational Highlights and Financial Results for the Period Ended March 31, 2021 [Jun-02-21 08:01PM]
19-11-2020	AH		MESO	Mesoblast Limited	1,380	-0.21	0.08	0.00	Mesoblast EPS beats by $0.22, misses on revenue [11/19/2020 5:43 PM]	13.84	2.05 (17.39%)	13.70	1.91 (16.20%)	3.12 - 21.28	1,931,053	336,440	63,874
Mesoblast EPS beats by $0.22, misses on revenue [11/19/2020 5:43 PM] Mesoblast inks deal with Novartis to develop COVID-19/ARDS stem cell therapy, shares +17% [11/20/2020 1:45 AM]